EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Immune checkpoint inhibition in undifferentiated cervical sarcoma with early pelvic recurrence: a case report

Yazhu Li, Jing Li, Huifang Liu, Qiting Tang, Limei Wang

Frontiers in Oncology · 21.04.2026 · 16

DOI: 10.3389/fonc.2026.1783604 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 21.04.2026. Verfasst von Yazhu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Undifferentiated cervical sarcoma is an extremely rare and highly aggressive malignant mesenchymal tumor. It is associated with a poor prognosis, limited responsiveness to conventional chemotherapy and radiotherapy, and a lack of standardized treatment strategies. Case presentation We report a 56-year-old postmenopausal woman who presented with vaginal bleeding and was diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage IIB undifferentiated cervical sarcoma. She underwent a modified laparoscopic radical hysterectomy with bilateral salpingo-oophorectomy, and gross intraoperative findings confirmed parametrial involvement. Postoperatively, she received three cycles of adjuvant chemotherapy. However, two months after surgery, during chemotherapy, she developed vaginal cuff bleeding and pelvic recurrence. Immunohistochemical analysis demonstrated programmed death-ligand 1 (PD-L1) positivity. The patient was subsequently treated with toripalimab monotherapy for six cycles, achieving complete tumor regression and a clinical complete response. This was followed by four cycles of consolidation immunotherapy. At the most recent follow-up, the patient remained disease-free.

Conclusion

This case highlights the diagnostic challenges and aggressive clinical behavior of undifferentiated cervical sarcoma and suggests a potential role for immune checkpoint inhibition in PD-L1-positive recurrent disease. Further studies are needed to confirm the findings.

Schlagwörter

Stichwörter der Autor:innen

PD-L1immune checkpoint inhibitorrecurrent gynecologic malignancytoripalimabundifferentiated cervical sarcoma

Autor:innen und Institutionen

  • Department of Gynecology, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.
  • Department of Pathology, The Seventh Medical Center of Chinese PLA General Hospital, Beijing, China.

Zitieren

APA

Li, Y., Li, J., Liu, H., Tang, Q., & Wang, L. (2026). Immune checkpoint inhibition in undifferentiated cervical sarcoma with early pelvic recurrence: a case report. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1783604

Vancouver

Li Y, Li J, Liu H, Tang Q, Wang L. Immune checkpoint inhibition in undifferentiated cervical sarcoma with early pelvic recurrence: a case report. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1783604

BibTeX
@article{Li2026,
  author = {Li, Yazhu and Li, Jing and Liu, Huifang and Tang, Qiting and Wang, Limei},
  title = {Immune checkpoint inhibition in undifferentiated cervical sarcoma with early pelvic recurrence: a case report},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1783604}
}
Kostenlos starten →